Feedback / Questions
aritinercept (AUR200) - Aurinia Pharmaceuticals
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
(clinicaltrials.gov)
-
May 20, 2026 -
P1/2 | N=81 | Recruiting | Sponsor: Aurinia Pharmaceuticals Inc.
New P1/2 trial
•
CNS Disorders • Myasthenia Gravis
http://clinicaltrials.gov/ct2/show/NCT07596901
May 20, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next